Current report 17/2024 – Positive Phase II top – line results for CPL’ 36, a PDE10A inhibitor in the treatment of acute schizophrenia

In reference to current report No. 26/2020 of September 30, 2020 on obtaining consent to start a Phase II clinical trial on a drug based on CPL’36, an innovative PDE10A inhibitor in patients with psychotic exacerbation of schizophrenia, the Management Board of Celon Pharma S.A. (the “Company”) announces positive Phase II top-line results of CPL’36,Read more »

Current report 11/2024 – Results of phase II clinical trial for CPL’ 116, a JAK/ROCK dual inhibitor in the treatment of Rheumatoid Arthritis (RA)

In reference to current reports 36/2021 on the successful completion of phase I clinical trial and 47/2021 on submission of an application for consent to commence a phase II trial of an innovative JAK/ROCK inhibitor – CPL 409116 – in the treatment of Rheumatoid Arthritis (RA), the Company’s Management Board hereby informs that on JuneRead more »

Current report No. 7/2024 – Opinion of the Supervisory’s Board on the Management Board’s recommendation on the payment of the dividend

Legal basis: Article 17 section 1 of the Market Abuse Regulation (MAR) – inside information. Date: 24/05/2024, g.17:13 In relation to the current report no. 5/2024 of 23 May 2024 on Management Board’s recommendation on the payment of the dividend, the Management Board of Celon Pharma S.A. (“Company”) hereby informs that on 24 May 2024 theRead more »

Current report No. 6/2024 – Notice on the convening of the Ordinary General Meeting of Celon Pharma S.A. on June 21, 2024 with draft resolutions

The Management Board of Celon Pharma S.A. (“the Company”), acting pursuant to Article 395 § 1, Article 399 § 1, Article 402 (1) and Article 402 (2) of the Commercial Companies Code, hereby convenes the Ordinary General Meeting (“Ordinary General Meeting”) on June 21, 2024 to be held at 09:30 AM at the Company’s ResearchRead more »

Current report No. 3/2024 – Informing about the medicinal product ZARIXA to the pharmaceutical market regulators

In reference to current report No. 24/2023, the Management Board of Celon Pharma S.A. (“Company”) of December 21, 2023 on the decision of the President of the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (“President of the Office for Registration of Medicinal Product”) concerning the issuance of a marketing authorization forRead more »

Current report 4/2024 – Celon enters into collaboration agreements with Tang Capital to create Novohale Therapeutics, LLC and advance Falkieri into global Phase 3 development for bipolar depression; and delayed disclosure of confidential information about the signing of a term sheet.

On 4 April 2024, Celon Pharma S.A. (the “Company” or “Celon”) and Tang Capital Management, LLC signed a non-binding term sheet (the “Term Sheet”) setting out the terms and conditions of the collaboration agreements between the Company and Tang Capital Management, LLC and its controlled affiliates (“Tang Capital”), which provided for an investment by TangRead more »